Legal proceedings for Supha Pharmachem's insolvency resolution.
The Mumbai bench of the National Company Law Tribunal (NCLT) has initiated the Corporate Insolvency Resolution Process (CIRP) for BSE-listed Supha Pharmachem following a payment default. This decision marks a critical juncture for the pharmaceutical company as it seeks to restructure its financial obligations under the insolvency framework.
Rajesh Jhunjhunwala has been appointed as the interim resolution professional (IRP). Jhunjhunwala will oversee the initial stages of the CIRP, including the assessment of Supha Pharmachem’s assets and liabilities, and the formation of a committee of creditors (CoC).
The admission of Supha Pharmachem into CIRP reflects increasing financial pressures on pharmaceutical companies amid evolving market dynamics. The resolution process will determine whether the company can be successfully restructured or will face liquidation.
About the Author
